Evidence map›Paper›PMID 35641545›Full record

ArticleScientific reports2022

High-resolution analysis of long-term serum antibodies in humans following convalescence of SARS-CoV-2 infection.

Antonio Facciuolo, Erin Scruten, Sean Lipsit, Amanda Lang, Zoë Parker Cates, Jocelyne M Lew, Darryl Falzarano, Volker Gerdts, Anthony J Kusalik, Scott Napper

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. ACS pharmacology & translational science · 2025
    Article
  3. Article
  4. Article
  5. The Impact of Serum/Plasma Proteomics on SARS-CoV-2 Diagnosis and Prognosis.International journal of molecular sciences · 2024
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Antonio FacciuoloVaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Saskatoon, SK, Canada.
Erin ScrutenVaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Saskatoon, SK, Canada.
Sean LipsitVaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Saskatoon, SK, Canada.
Amanda LangRoy Romanow Provincial Laboratory, Saskatchewan Health Authority, Regina, SK, Canada.
Zoë Parker CatesDepartment of Computer Science, University of Saskatchewan, Saskatoon, SK, Canada.
Jocelyne M LewVaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Saskatoon, SK, Canada.
Darryl FalzaranoVaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Saskatoon, SK, Canada.
Volker GerdtsVaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Saskatoon, SK, Canada.
Anthony J KusalikDepartment of Computer Science, University of Saskatchewan, Saskatoon, SK, Canada.
Scott NapperVaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Saskatoon, SK, Canada. scott.napper@usask.ca.
University of Saskatchewan · CASaskatchewan Health Authority · CA

Funding

CIHR OV5-170349
6 · The paper itself

Abstract

Long-term antibody responses to SARS-CoV-2 have focused on responses to full-length spike protein, specific domains within spike, or nucleoprotein. In this study, we used high-density peptide microarrays representing the complete proteome of SARS-CoV-2 to identify binding sites (epitopes) targeted by antibodies present in the blood of COVID-19 resolved cases at 5 months post-diagnosis. Compared to previous studies that evaluated epitope-specific responses early post-diagnosis (< 60 days), we found that epitope-specific responses to nucleoprotein and spike protein have contracted, and that responses to membrane protein have expanded. Although antibody titers to full-length spike and nucleoprotein remain steady over months, taken together our data suggest that the population of epitope-specific antibodies that contribute to this reactivity is dynamic and evolves over time. Further, the spike epitopes bound by polyclonal antibodies in COVID-19 convalescent serum samples aligned with known target sites that can neutralize viral activity suggesting that the maintenance of these antibodies might provide rapid serological immunity. Finally, the most dominant epitopes for membrane protein and spike showed high diagnostic accuracy providing novel biomarkers to refine blood-based antibody tests. This study provides new insights into the specific regions of SARS-CoV-2 targeted by serum antibodies long after infection.

Indexed as

Antibodies, ViralConvalescenceCOVID-19Coronavirus Nucleocapsid ProteinsCOVID-19 SerotherapyEpitopesHumansImmunization, PassivePhosphoproteinsSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, ViralCoronavirus Nucleocapsid ProteinsEpitopesnucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID35641545
PMCPMC9152668
OpenAlexW4281692682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.